Cargando…
Protocol of a randomised trial of teriparatide followed by zoledronic acid to reduce fracture risk in adults with osteogenesis imperfecta
INTRODUCTION: Osteogenesis imperfecta (OI) is a rare genetic disease associated with multiple fractures throughout life. It is often treated with osteoporosis medications but their effectiveness at preventing fractures is unknown. The Treatment of Osteogenesis Imperfecta with Parathyroid Hormone and...
Autores principales: | Hald, Jannie D, Keerie, Catriona, Weir, Christopher J, Javaid, Muhammad K, Lam, Wayne, Osborne, Patricia, Walsh, Jennifer, Langdahl, Bente L, Ralston, Stuart H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668140/ https://www.ncbi.nlm.nih.gov/pubmed/37993151 http://dx.doi.org/10.1136/bmjopen-2023-078164 |
Ejemplares similares
-
Zoledronate in the prevention of Paget’s (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1-mediated Paget’s disease of bone
por: Cronin, Owen, et al.
Publicado: (2019) -
The dental perspective on osteogenesis imperfecta in a Danish adult population
por: Thuesen, Kirstine Juhl, et al.
Publicado: (2018) -
Management of Osteogenesis Imperfecta
por: Ralston, Stuart H., et al.
Publicado: (2020) -
Oral health‐related quality of life in X‐linked hypophosphataemia and osteogenesis imperfecta
por: Gjørup, Hans, et al.
Publicado: (2020) -
Beneficial Effects of Zoledronic Acid on Tendons of the Osteogenesis Imperfecta Mouse (Oim)
por: Chretien, Antoine, et al.
Publicado: (2023)